Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 626,017
  • Shares Outstanding, K 50,526
  • Annual Sales, $ 82,500 K
  • Annual Income, $ 17,859 K
  • 36-Month Beta 1.38
  • Price/Sales 7.01
  • Price/Cash Flow 33.07
  • Price/Book 29.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.32
  • Prior Year 0.80
  • Growth Rate Est. (year over year) -135.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.44 +31.89%
on 12/21/18
12.81 -2.81%
on 01/18/19
+2.43 (+24.25%)
since 12/18/18
3-Month
9.07 +37.27%
on 11/20/18
12.81 -2.81%
on 01/18/19
+0.76 (+6.50%)
since 10/18/18
52-Week
8.11 +53.51%
on 01/19/18
15.08 -17.44%
on 03/21/18
+4.29 (+52.57%)
since 01/18/18

Most Recent Stories

More News
ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday,...

JPM : 104.59 (+1.62%)
CCXI : 12.45 (+0.48%)
ChemoCentryx's Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference

-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo --

CCXI : 12.45 (+0.48%)
New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ralph Lauren Corporation...

SXCP : 12.50 (+1.79%)
PRAA : 29.76 (+1.88%)
DK : 33.47 (+1.67%)
RL : 111.57 (+3.42%)
CECE : 7.06 (+0.43%)
CCXI : 12.45 (+0.48%)
SXC : 10.76 (+2.77%)
ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November...

CCXI : 12.45 (+0.48%)
ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 12.00% and -22.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CCXI : 12.45 (+0.48%)
ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights

-- Large, controlled clinical trial of avacopan in Hidradenitis Suppurativa (HS) on track to launch in late 2018 -

CCXI : 12.45 (+0.48%)
ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018. ChemoCentryx executive management...

CCXI : 12.45 (+0.48%)
Earnings Preview: ChemoCentryx (CCXI) Q3 Earnings Expected to Decline

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CCXI : 12.45 (+0.48%)
Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)

-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ADVOCATE Phase III Pivotal Trial in ANCA-Associated Vasculitis --

CCXI : 12.45 (+0.48%)
Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ChemoCentryx, Inc. (NASDAQ:CCXI),...

HK : 1.91 (+3.80%)
AFI : 13.26 (+0.23%)
SVM : 2.00 (-2.44%)
CCXI : 12.45 (+0.48%)
KRNT : 20.09 (+2.08%)
NLNK : 1.52 (+0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CCXI with:

Business Summary

ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

See More

Key Turning Points

2nd Resistance Point 13.10
1st Resistance Point 12.77
Last Price 12.45
1st Support Level 12.16
2nd Support Level 11.88

See More

52-Week High 15.08
Last Price 12.45
Fibonacci 61.8% 12.42
Fibonacci 50% 11.59
Fibonacci 38.2% 10.77
52-Week Low 8.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar